Delaying the Onset of Nearsightedness Until Treatment Study
Stopped sIRB determined feasibility study could not be done because of no benefits of the treatment drops in short time violated FDA requirements
Conditions
Interventions
- DRUG: Atropine Ophthalmic
Sponsor
Ohio State University
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]